Sharps Technology Reports FY Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 06 2026
0mins
Source: seekingalpha
- Financial Overview: Sharps Technology's FY GAAP EPS stands at -$10.68, indicating significant financial challenges that may lead to a decline in investor confidence.
- Revenue Performance: The reported revenue of $0.2 million falls short of market expectations, highlighting the company's competitive disadvantages that could impact future financing capabilities and operational strategies.
- Financial Health: The ongoing losses and low revenue levels may compel Sharps Technology to reassess its business model and cost structure to achieve sustainable growth and attract investor interest.
- Market Reaction Outlook: Given the poor financial performance, the market is expected to react negatively to Sharps Technology's stock price, prompting investors to closely monitor subsequent strategic adjustments and management responses.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STSS
About STSS
Sharps Technology, Inc. is a medical device and pharmaceutical packaging company. The Company is engaged in offering patented smart-safety syringe products to the healthcare industry. The Company's smart safety syringe products, such as Securgard, Sologard, and Sharps Provensa, are ultra-low waste syringes that incorporate both passive and active safety and reuse prevention features. It Sharps Securegard and Sologard safety syringe product lines incorporate both active and passive safety features and have been designed to address the primary administration concerns with syringe delivery systems, including accidental needlestick injuries, wasted medicine/dead space and reuse prevention. It also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. It has a manufacturing facility in Hungary and is pursuing plans to expand its manufacturing capacity in the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sharps Technology Rebrands as SkyAI to Focus on Global Finance Platform
- Rebranding Initiative: Sharps Technology has rebranded as SkyAI to reflect its strategic focus on establishing a financial platform for developing countries in the Global South, which is expected to enhance the company's influence in emerging markets.
- Stock Trading Transition: The company's common stock will cease trading under the symbol 'STSS' on May 28, 2026, and will begin trading on Nasdaq under the new ticker 'SKYA', marking a significant step in its internationalization efforts.
- Overseas Headquarters Establishment: SkyAI has established its overseas operational headquarters in Hong Kong, leveraging the city's robust fintech hub to secure relevant licensing and recruit top engineering talent to support its global expansion plans.
- Infrastructure Optimization: The new platform will utilize Solana blockchain technology to connect various assets and markets, aiming to improve financial systems in Asia, Latin America, and Africa by providing seamless access to U.S. dollar savings amidst high inflation in local currencies.
See More
Sharps Technology Adopts Stockholder Rights Plan to Protect Interests
- Rights Plan Implementation: Sharps Technology's Board of Directors has adopted a limited-duration stockholder rights plan aimed at protecting shareholder interests, ensuring that all shareholders can realize the value of their investments, thereby enhancing corporate governance.
- Control Acquisition Prevention: The plan is designed to reduce the likelihood that any individual or group could gain control of the company through open market accumulation without paying an appropriate control premium, thus safeguarding shareholder rights.
- Rights Distribution Details: The company will issue one preferred share purchase right for each outstanding share to shareholders of record as of May 26, 2026, which will initially be non-exercisable, providing protection against potential future acquisitions and enhancing investment security for shareholders.
- Strategic Focus: The Board emphasizes that this measure is to guard against improper acquisition tactics while remaining focused on executing the company's transformational strategy to drive long-term value growth and maximize shareholder interests.
See More
Sharps Technology Adopts Stockholder Rights Plan to Protect Interests
- Stockholder Rights Plan: Sharps Technology's Board of Directors has adopted a limited-duration stockholder rights plan aimed at protecting shareholder interests and preventing any individual or group from gaining control of the company through open market accumulation without paying an appropriate control premium, thereby ensuring all shareholders can realize their investment value.
- Rights Distribution Details: Under this plan, Sharps Technology will issue one preferred share purchase right for each outstanding share of common stock to shareholders of record as of May 26, 2026; although these rights will initially be non-exercisable, they will trade with the common stock, enhancing shareholders' potential equity.
- Conditions for Exercising Rights: The plan stipulates that rights will only become exercisable if a person or group acquires 15% or more of the common stock, allowing holders to purchase shares at an exercise price of $10.00 per right, ensuring shareholder interests are protected during control changes.
- Strategic Implications: The Board views the adoption of this rights plan as a prudent measure against improper control tactics, providing the company with sufficient time to make informed decisions that drive long-term value growth and maintain competitiveness in the medical device market.
See More
Sharps Technology Reports FY Results
- Financial Overview: Sharps Technology reported a FY GAAP EPS of -$10.68, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Figures: The company reported revenue of $7.0 million, and despite the revised figure, it reflects the company's struggles in a competitive market, potentially leading to difficulties in future financing.
- Financial Correction: The release emphasizes the company's efforts to ensure data accuracy, although the negative earnings may attract regulatory scrutiny, impacting its operational credibility.
- Market Reaction Expectations: Given the reported losses, the market is likely to respond negatively to Sharps Technology's stock, potentially leading to further declines in share price.
See More
Sharps Technology Reports FY Financial Results
- Financial Overview: Sharps Technology's FY GAAP EPS stands at -$10.68, indicating significant financial challenges that may lead to a decline in investor confidence.
- Revenue Performance: The reported revenue of $0.2 million falls short of market expectations, highlighting the company's competitive disadvantages that could impact future financing capabilities and operational strategies.
- Financial Health: The ongoing losses and low revenue levels may compel Sharps Technology to reassess its business model and cost structure to achieve sustainable growth and attract investor interest.
- Market Reaction Outlook: Given the poor financial performance, the market is expected to react negatively to Sharps Technology's stock price, prompting investors to closely monitor subsequent strategic adjustments and management responses.
See More
Sharps Technology Reports Strong Financial Results for 2025
- Significant SOL Holdings: As of December 31, 2025, Sharps Technology held over 2 million SOL, with approximately 95% actively staked at a gross annualized yield of around 7%, providing a stable income stream that enhances the company's financial stability.
- Asset Growth: The company reported total assets of $269.1 million, a substantial increase from $7.3 million at the end of 2024, demonstrating the success of its digital asset strategy and boosting stockholders' equity to $264.4 million, indicating a significant improvement in financial health.
- Revenue Structure Optimization: For FY 2025, the company generated total revenue of approximately $7.0 million, including $6.8 million in net staking revenue, reflecting successful positioning in the digital asset space while also achieving revenue from medical device distribution, showcasing a diversified income stream.
- Expanded Strategic Partnerships: Sharps launched its branded validator through Coinbase's institutional infrastructure and established collaborations with multiple strategic partners, including Crypto.com and BitGo, which not only enhance the company's market position but also lay a solid foundation for future growth.
See More
Sharps Technology Rebrands as SkyAI to Focus on Global Finance Platform
- Rebranding Initiative: Sharps Technology has rebranded as SkyAI to reflect its strategic focus on establishing a financial platform for developing countries in the Global South, which is expected to enhance the company's influence in emerging markets.
- Stock Trading Transition: The company's common stock will cease trading under the symbol 'STSS' on May 28, 2026, and will begin trading on Nasdaq under the new ticker 'SKYA', marking a significant step in its internationalization efforts.
- Overseas Headquarters Establishment: SkyAI has established its overseas operational headquarters in Hong Kong, leveraging the city's robust fintech hub to secure relevant licensing and recruit top engineering talent to support its global expansion plans.
- Infrastructure Optimization: The new platform will utilize Solana blockchain technology to connect various assets and markets, aiming to improve financial systems in Asia, Latin America, and Africa by providing seamless access to U.S. dollar savings amidst high inflation in local currencies.
See More
Sharps Technology Adopts Stockholder Rights Plan to Protect Interests
- Rights Plan Implementation: Sharps Technology's Board of Directors has adopted a limited-duration stockholder rights plan aimed at protecting shareholder interests, ensuring that all shareholders can realize the value of their investments, thereby enhancing corporate governance.
- Control Acquisition Prevention: The plan is designed to reduce the likelihood that any individual or group could gain control of the company through open market accumulation without paying an appropriate control premium, thus safeguarding shareholder rights.
- Rights Distribution Details: The company will issue one preferred share purchase right for each outstanding share to shareholders of record as of May 26, 2026, which will initially be non-exercisable, providing protection against potential future acquisitions and enhancing investment security for shareholders.
- Strategic Focus: The Board emphasizes that this measure is to guard against improper acquisition tactics while remaining focused on executing the company's transformational strategy to drive long-term value growth and maximize shareholder interests.
See More
Sharps Technology Adopts Stockholder Rights Plan to Protect Interests
- Stockholder Rights Plan: Sharps Technology's Board of Directors has adopted a limited-duration stockholder rights plan aimed at protecting shareholder interests and preventing any individual or group from gaining control of the company through open market accumulation without paying an appropriate control premium, thereby ensuring all shareholders can realize their investment value.
- Rights Distribution Details: Under this plan, Sharps Technology will issue one preferred share purchase right for each outstanding share of common stock to shareholders of record as of May 26, 2026; although these rights will initially be non-exercisable, they will trade with the common stock, enhancing shareholders' potential equity.
- Conditions for Exercising Rights: The plan stipulates that rights will only become exercisable if a person or group acquires 15% or more of the common stock, allowing holders to purchase shares at an exercise price of $10.00 per right, ensuring shareholder interests are protected during control changes.
- Strategic Implications: The Board views the adoption of this rights plan as a prudent measure against improper control tactics, providing the company with sufficient time to make informed decisions that drive long-term value growth and maintain competitiveness in the medical device market.
See More
Sharps Technology Reports FY Results
- Financial Overview: Sharps Technology reported a FY GAAP EPS of -$10.68, indicating significant challenges in profitability that could undermine investor confidence.
- Revenue Figures: The company reported revenue of $7.0 million, and despite the revised figure, it reflects the company's struggles in a competitive market, potentially leading to difficulties in future financing.
- Financial Correction: The release emphasizes the company's efforts to ensure data accuracy, although the negative earnings may attract regulatory scrutiny, impacting its operational credibility.
- Market Reaction Expectations: Given the reported losses, the market is likely to respond negatively to Sharps Technology's stock, potentially leading to further declines in share price.
See More
Sharps Technology Reports FY Financial Results
- Financial Overview: Sharps Technology's FY GAAP EPS stands at -$10.68, indicating significant financial challenges that may lead to a decline in investor confidence.
- Revenue Performance: The reported revenue of $0.2 million falls short of market expectations, highlighting the company's competitive disadvantages that could impact future financing capabilities and operational strategies.
- Financial Health: The ongoing losses and low revenue levels may compel Sharps Technology to reassess its business model and cost structure to achieve sustainable growth and attract investor interest.
- Market Reaction Outlook: Given the poor financial performance, the market is expected to react negatively to Sharps Technology's stock price, prompting investors to closely monitor subsequent strategic adjustments and management responses.
See More
Sharps Technology Reports Strong Financial Results for 2025
- Significant SOL Holdings: As of December 31, 2025, Sharps Technology held over 2 million SOL, with approximately 95% actively staked at a gross annualized yield of around 7%, providing a stable income stream that enhances the company's financial stability.
- Asset Growth: The company reported total assets of $269.1 million, a substantial increase from $7.3 million at the end of 2024, demonstrating the success of its digital asset strategy and boosting stockholders' equity to $264.4 million, indicating a significant improvement in financial health.
- Revenue Structure Optimization: For FY 2025, the company generated total revenue of approximately $7.0 million, including $6.8 million in net staking revenue, reflecting successful positioning in the digital asset space while also achieving revenue from medical device distribution, showcasing a diversified income stream.
- Expanded Strategic Partnerships: Sharps launched its branded validator through Coinbase's institutional infrastructure and established collaborations with multiple strategic partners, including Crypto.com and BitGo, which not only enhance the company's market position but also lay a solid foundation for future growth.
See More
